Updates in the Treatment of Mantle Cell Lymphoma

Article

This article discusses the current treatment landscape and therapeutic strategies for mantle cell lymphoma, the role of Bruton tyrosine kinase inhibitor therapies in MCL, and insights on new regimens and ongoing clinical trials from leading experts in hematologic malignancies.

Related Videos
Jean L. Koff, MD, MS
Lori A. Leslie, MD
Changchun Deng, MD, PhD
Guenther Koehne, MD, PhD
Ibrahim Aldoss, MD
Andrew P. Jallouk, BS, MD, PhD, assistant professor, Vanderbilt University
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Ibrahim Aldoss, MD
Kateryna Fedorov, MD, assistant professor, hematology-oncology, Vanderbilt University Medical Center
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Related Content
Gulrayz Ahmed, MD, the Medical College of Wisconsin

Retrospective Analysis Shows Efficacy and Safety of CAR T-Cell Therapy in MCL With SCNS

May 14th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
OncLive On Air Podcast Recap

Revisit Every OncLive On Air Episode From April 2024

May 13th 2024
Article
Matthew Lunning, DO, FACP

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

November 30th 2023
Podcast
Harout Semerjian, CEO of GlycoMimetics

Uproleselan Plus Chemotherapy Misses OS End Point in R/R AML

May 6th 2024
Article
Leland Metheny, MD, Case Western Reserve University

AML, ALL, and Glioblastoma Multiforme Clinical Trials Seek to Push the Needle Forward

May 6th 2024
Article